Year
DEALS // DEV.
Country
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target
Lead Product(s) : Molnupiravir
Therapeutic Area : Infections and Infectious Diseases
Study Phase : Approved
Recipient : Aurigene Pharmaceutical Services
Deal Size : Undisclosed
Deal Type : Licensing Agreement
Details : Fermenta Biotech will exclusively license its biocatalytic technology for synthesis of Molnupiravir (Molflu) and supply its enzyme Candida Antarctica B Lipase (CAL B) to Aurigene. Molnupiravir API manufactured by Aurigene will be utilised by Dr Reddy’s...
Brand Name : Molflu
Molecule Type : Small molecule
Upfront Cash : Undisclosed
January 21, 2022
Lead Product(s) : Molnupiravir
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Approved
Recipient : Aurigene Pharmaceutical Services
Deal Size : Undisclosed
Deal Type : Licensing Agreement
LOOKING FOR A SUPPLIER?
Reset All
